[go: up one dir, main page]

PT3003383T - Composição sólida para administração oral que contém ácido ibandrónico ou um seu sal farmaceuticamente aceitável e vitamina d - Google Patents

Composição sólida para administração oral que contém ácido ibandrónico ou um seu sal farmaceuticamente aceitável e vitamina d

Info

Publication number
PT3003383T
PT3003383T PT14730606T PT14730606T PT3003383T PT 3003383 T PT3003383 T PT 3003383T PT 14730606 T PT14730606 T PT 14730606T PT 14730606 T PT14730606 T PT 14730606T PT 3003383 T PT3003383 T PT 3003383T
Authority
PT
Portugal
Prior art keywords
vitamin
pharmaceutically acceptable
acceptable salt
oral administration
solid composition
Prior art date
Application number
PT14730606T
Other languages
English (en)
Inventor
Pedro Silva Serra João
Maria Soares Isabel
Original Assignee
Tecnimede Sociedade Tecnico Medicinal S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50943510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3003383(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tecnimede Sociedade Tecnico Medicinal S filed Critical Tecnimede Sociedade Tecnico Medicinal S
Publication of PT3003383T publication Critical patent/PT3003383T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT14730606T 2013-05-31 2014-05-30 Composição sólida para administração oral que contém ácido ibandrónico ou um seu sal farmaceuticamente aceitável e vitamina d PT3003383T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PT106978A PT106978A (pt) 2013-05-31 2013-05-31 Composição sólida oral contendo ácido ibandrónico e vitamina d

Publications (1)

Publication Number Publication Date
PT3003383T true PT3003383T (pt) 2019-01-16

Family

ID=50943510

Family Applications (2)

Application Number Title Priority Date Filing Date
PT106978A PT106978A (pt) 2013-05-31 2013-05-31 Composição sólida oral contendo ácido ibandrónico e vitamina d
PT14730606T PT3003383T (pt) 2013-05-31 2014-05-30 Composição sólida para administração oral que contém ácido ibandrónico ou um seu sal farmaceuticamente aceitável e vitamina d

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT106978A PT106978A (pt) 2013-05-31 2013-05-31 Composição sólida oral contendo ácido ibandrónico e vitamina d

Country Status (16)

Country Link
US (1) US20160106766A1 (pt)
EP (1) EP3003383B1 (pt)
BR (1) BR112015029897A2 (pt)
CL (1) CL2015003468A1 (pt)
DK (1) DK3003383T3 (pt)
ES (1) ES2705074T3 (pt)
HU (1) HUE040666T2 (pt)
LT (1) LT3003383T (pt)
MA (1) MA38688B1 (pt)
MX (1) MX364680B (pt)
PL (1) PL3003383T3 (pt)
PT (2) PT106978A (pt)
RS (1) RS58133B1 (pt)
SI (1) SI3003383T1 (pt)
TR (1) TR201821157T4 (pt)
WO (1) WO2014193255A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3095447T (pt) 2006-02-03 2022-01-24 Opko Renal Llc Tratamento da insuficiência e deficiência de vitamina d com 25-hidroxivitamina d2 e 25-hidroxivitamina d3
SI2037936T1 (sl) 2006-06-21 2014-11-28 Opko Renal, Llc Postopek zdravljenja in prepreäśevanja sekundarnega hiperparatiroidizma
EP2148684B1 (en) 2007-04-25 2013-01-16 Cytochroma Inc. Method of treating vitamin d insufficiency and deficiency
SI2481400T1 (sl) 2007-04-25 2014-11-28 Opko IP Holdings II, Inc. Nadzorovano oralno sproščanje sestavkov, ki vsebujejo spojino vitamina D in voskasti nosilec
LT2552484T (lt) 2010-03-29 2020-04-27 Opko Ireland Global Holdings, Ltd. Būdai ir kompozicijos, skirti paratiroidų lygiams sumažinti
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
MY198547A (en) 2016-03-28 2023-09-04 Opko Ireland Global Holdings Ltd Methods of vitamin d treatment

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100317935B1 (ko) 1999-10-20 2001-12-22 유승필 대사성 골질환 치료용 약제조성물 및 이의 제조방법
US6468559B1 (en) * 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
US20050070504A1 (en) * 2001-12-21 2005-03-31 The Procter & Gamble Co. Risedronate compositions and their methods of use
WO2003086415A1 (en) 2002-04-05 2003-10-23 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
US20080139514A1 (en) * 2006-11-29 2008-06-12 Subhash Pandurang Gore Diphosphonic acid pharmaceutical compositions
AU2007335155A1 (en) * 2006-12-20 2008-06-26 Mylan Pharmaceuticals Ulc A composition containing a bisphosphonic acid in combination with vitamin D
EP1972341A1 (en) 2007-03-23 2008-09-24 Novartis AG Pharmaceutical compositions comprising a bisphosphonate and vitamin D
US20100158998A1 (en) * 2008-12-23 2010-06-24 Michael Fox Formulations comprising vitamin d or derivatives thereof
WO2010117346A2 (en) * 2009-04-10 2010-10-14 Mahmut Bilgic Stable pharmaceutical compositions with high bioavailibility
IT1396937B1 (it) * 2009-11-26 2012-12-20 Bruzzese Formulazioni di bisfosfonati e vitamina d idonee alla somministrazione intermittente per via intramuscolare e sottocutanea
KR101230178B1 (ko) * 2010-06-10 2013-02-06 주식회사 네비팜 골다공증 예방 또는 치료용 조성물 및 이의 제조방법
EP2680826B1 (en) * 2011-03-02 2017-08-23 D3 Pharma Limited Vitamin d composition

Also Published As

Publication number Publication date
WO2014193255A1 (en) 2014-12-04
EP3003383B1 (en) 2018-10-03
EP3003383A1 (en) 2016-04-13
US20160106766A1 (en) 2016-04-21
ES2705074T3 (es) 2019-03-21
LT3003383T (lt) 2019-03-12
DK3003383T3 (en) 2019-01-28
PL3003383T3 (pl) 2019-04-30
TR201821157T4 (tr) 2019-02-21
MA38688B1 (fr) 2018-08-31
MX364680B (es) 2019-05-03
HUE040666T2 (hu) 2019-08-28
MX2015016497A (es) 2016-09-08
CL2015003468A1 (es) 2016-07-22
SI3003383T1 (sl) 2019-03-29
MA38688A1 (fr) 2017-07-31
PT106978A (pt) 2014-12-02
BR112015029897A2 (pt) 2017-07-25
RS58133B1 (sr) 2019-02-28

Similar Documents

Publication Publication Date Title
ZA201509239B (en) Amorphous letermovir and solid pharmaceutical formulations thereof for oral administration
PT3003383T (pt) Composição sólida para administração oral que contém ácido ibandrónico ou um seu sal farmaceuticamente aceitável e vitamina d
IL246377A0 (en) Pharmaceutical preparations for oral administration
PT3003285T (pt) Forma de administração farmacêutica sólida para libertação de pelo menos dois princípios ativos farmacêuticos na cavidade oral
EP3038465A4 (en) Oral pharmaceutical formulation of omarigliptin
ZA201405756B (en) Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof
ZA201306395B (en) New low side effect pharmaceutical composition containing antituberculosis drugs
LT2983650T (lt) Peroralinė farmacinė kompozicija, apimanti maskuoto skonio n-acetilcisteiną
IL240666A0 (en) Pharmaceutical preparations for oral administration and their uses
IL241367A0 (en) Pharmaceutical composition for oral dual use of tablets of sulfate salts and methods of using it
EP3020417A4 (en) Pharmaceutical composition for respiratory administration
LT3318259T (lt) Stabili farmacinė kompozicija, skirta peroraliniam vartojimui
EP3290037A4 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
IL239958A (en) A chewable oral preparation and process for preparing it
ZA201604100B (en) Gastro-retentive oral pharmaceutical compositions
EP2979698A4 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
EP3162368A4 (en) Pharmaceutical composition for oral administration
EP3082783A4 (en) Stable oral pharmaceutical composition
SI2988782T1 (sl) Odmerne oblike za peroralno dajanje učinkovin
SI3079672T1 (sl) Farmacevtski sestavek, ki vsebuje farmacevtsko sprejemljivo sol razagilina
HK1230071A1 (en) Oral pharmaceutical composition